Applications of P-Hydroxybenzoic Acid Ethyl Ester Sodium Salt in Industrial Manufacturing

As a direct manufacturer, we supply P-Hydroxybenzoic Acid Ethyl Ester Sodium Salt for specialized industrial applications where consistent quality, regulatory adherence, and precise formulation management are essential. Our material integrates efficiently into established downstream manufacturing workflows in select sectors with a proven record of end-product stability and safety.

1. Preservation Systems for Water-Based Personal Care

Personal care manufacturers rely on the sodium salt of ethyl paraben for microbial control in aqueous creams, lotions, and rinse-off toiletries, as regulations limit available preservative choices. Our product disperses easily in water-based matrices and helps inhibit bacterial and fungal growth throughout retail shelf life, even in open-jar packaging. Performance validation depends on robust challenge testing as dictated by market regulations for leave-on and rinse-off applications targeting sensitive skin or multipurpose formulas.

Industry compliance standards

• EU Cosmetics Regulation (EC) No 1223/2009 — Annex V
• ASEAN Cosmetic Directive
• US FDA 21 CFR 700.3 (cosmetics)
• ISO 22716 GMP for Cosmetic Products

Typical usage ratio

• 0.1%–0.4% w/w; adjusted lower for combinations with other parabens or mild preservative boosters; careful not to exceed maximum authorized concentrations by jurisdiction

Downstream process integration

• Dissolved in aqueous phase at < 70°C prior to emulsion formation or addition of sensitive actives; typically incorporated in early batch steps to ensure homogeneity; compatible with emulsifiers and stabilizers

Final product types

• Hydrating face creams
• Moisturizing body lotions
• Micellar water cleansers
• Shower gels and liquid shampoos

2. Antimicrobial Additive in Ophthalmic and Nasal Solutions

When producing multi-dose eye drops or nasal sprays, pharmaceutical manufacturers select this raw material for its effective antimicrobial protection in buffered saline and isotonic vehicles, especially where heat sterilization cannot be applied. Our quality control ensures ultra-low bioburden and consistency in particle size, preventing phase separation or precipitation in clear solutions. Its rapid dissolution and low sensitization risk make it suitable for formulations requiring high patient tolerance.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) Monographs (for preservatives in eye drops)
• USP <771> Ophthalmic Products—Quality Tests
• WHO GMP for Pharmaceutical Production
• US FDA 21 CFR 200.50 (ophthalmic drug products)

Typical usage ratio

• 0.02%–0.1% w/v in ophthalmic/nasal solutions; exact dosage determined through stability and preservative effectiveness testing, with consideration for cumulative preservative load where other agents are present

Downstream process integration

• Uniformly dissolved prior to sterile filtration in solution preparation step, before sterile filling into dropper bottles; avoids heat degradation; compatible with phosphate, borate, and sodium chloride buffer systems

Final product types

• Lubricating eye drops
• Artificial tears with preservatives
• Buffered nasal drops and sprays

3. Shelf-life Extender in Low-pH Syrup and Liquid Oral Supplements

Producers of vitamin syrups and liquid nutraceuticals facing challenges with microbial control in acidic media use our sodium salt for stability and extended shelf life. Its solubility performance and low sensory impact at permitted levels support transparent labelling for “paraben-controlled” systems. The raw material maintains functionality through hot-fill processing and remains compatible with sweeteners, flavours, and ascorbic acid, provided pH and ionic profile are well managed.

Industry compliance standards

• FAO/WHO Codex Alimentarius — General Standard for Food Additives (CODEX STAN 192-1995)
• China GB 2760-2022 (National Food Safety Standard for Food Additives Use)
• EU Regulation (EC) No 1333/2008 on Food Additives
• ISO 22000 Food Safety Management Systems

Typical usage ratio

• 0.05%–0.15% w/v depending on product acidity, sugar and salt content, and combined preservative system; final level set after microbial challenge and sensory testing

Downstream process integration

• Incorporated into deionized water base with other preservative agents at room temperature, before active ingredients and sweeteners; solution may be heat-treated for filling or pasteurization

Final product types

• Children’s vitamin syrups
• Liquid herbal supplements
• Electrolyte and B-vitamin oral solutions

4. Antifungal Component in Industrial Water-Based Adhesives

Manufacturers producing water-dispersion adhesives for paper, labelling, and woodworking industries use our product to combat fungal growth in storage and open-use settings. Material compatibility with synthetic and modified natural polymer dispersions enables consistent batch-to-batch performance without gelling or phase separation. QC protocols include monitoring preservative depletion rates and validation through fungal challenge methods specific to the adhesive's intended market.

Industry compliance standards

• EN 923: Adhesives—Terms and Definitions and General Principles for Testing
• ASTM D2574 Standard Test Method for Resistance of Emulsion Paints to Attack by Fungi
• ISO 9001 Certified Production Systems
• German BgVV Guidelines for Consumer-Contact Adhesives

Typical usage ratio

• 0.1%–0.25% by weight, adjusted downward for short-shelf-life products or upward for high-humidity applications; level finalized after accelerated aging tests in relevant climatic chambers

Downstream process integration

• Added post-neutralization and pigment/additive blending, prior to viscosity adjustment and tank storage; monitored for compatibility with thickeners and latex dispersions

Final product types

• Ready-to-use wallpaper adhesives
• Casein-free school glues
• Wood bonding dispersions

5. Interim Preservative in Bulk Pharmaceutical Ingredients (APIs) Solution Storage

API manufacturers facing storage or transport of aqueous intermediates require prevention of bioburden build-up during periods before downstream synthesis or crystallization. The sodium salt acts as an interim preservative to stabilize high-purity intermediates prior to solvent switching or lyophilization, supporting GMP-mandated microbial control. Subsequent purification steps ensure its absence from registered API final forms in accordance with international pharmacopoeias and marketing authorizations.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• European Pharmacopoeia General Monograph 2034
• US FDA 21 CFR Parts 210–211
• WHO Technical Report Series, No. 957 (Annex 2)

Typical usage ratio

• 0.02%–0.08% w/v in holding solutions; removed or degraded during downstream purification steps (by extraction, ultrafiltration, recrystallization, or distillation)

Downstream process integration

• Dosed dissolved directly into intermediate aqueous phase following filtration and pH balancing; typically omitted at final isolation or drying stage; monitored by TOC and antimicrobial residue testing prior to release

Final product types

• Intermediate bulk solutions for antibiotic synthesis
• Aqueous intermediates for antipyretic APIs
• Buffered holding solutions for peptide precursors